The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Medical Research Grant
The Progeria Research Foundation (PRF) is the only organization in the world dedicated to discovering treatments and the cure for Progeria and its aging-related disorders. Progeria is a rare, fatal, “premature aging” disease that affects children, who die of cardiovascular disease (heart failure or stroke) at an average age of 14 years - the same diseases that affect millions of normal aging adults (atherosclerosis and stroke). Investigation of the disease mechanisms causing Progeria will help not only children with Progeria, but also has implications for heart attacks, strokes and other aging-related conditions.
PRF’s research focus is highly translational. Topics must fall within any of the following research priorities:
• Projects that are likely to lead to clinical treatment trials within 5 years. This includes the discovery and/or testing of candidate treatment compounds in cellbased or animal models of HGPS. Only proposals that test compounds in a progerin-producing animal or cell model will normally be considered. Analyses in non progerin-producing models are acceptable, but only as a comparison to progerin-producing models and with strong justification.
• Development of gene- and cell-based therapies to treat Progeria
• Assessment of natural history of disease that may be important to developing outcome measures in treatment trials (preclinical or clinical)
Awards are typically for 1-2 years in the range of $75,000/year.
Deadline for Letter of Intent: July 1, 2019; Jan. 2, 2020
Principal investigators must hold a faculty appointment or equivalent. Awards will be granted only to applicants affiliated with institutions with 501(c) 3 tax-exempt status, or the equivalent for foreign institutions. Project Facilitation for Awards Granted: A grant advisor, usually a member of the PRF Medical Research Committee, will be assigned to each funded project.